Enobia

Exited, Selected / By

Enobia developed the super-orphan drug Strensiq™ (asfotase alfa) for the treatment of Hypophosphatasia. Enobia was acquired by Alexion for $1.1 billion in 2022.

Location

Montreal, Canada

History

Acquired by Alexion Pharmaceuticals for $1.1 billion in 2022

Related companies

Terms & conditions
Cookie policy
Privacy policy

Registered in England No. 3941653 | VAT No. GB 765 3567 96

© 2017 Rosetta Capital Limited | Authorised and regulated by the Financial Conduct Authority

Website by Instinctif Partners
Rosetta Capital
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.